Overview
Zacks Rank #5 (Strong Sell) stock BioNTech (BNTX) is a German biotech firm that develops and commercializes immunotherapies and innovative cancer treatments based on individualized therapies and precision medicine. The company was founded in 2008 and is based in Mainz, Germany.
BioNTech was relatively obscure until the company partnered with pharmaceutical juggernaut Pfizer (PFE) to develop one of the first mRNA COVID-19 vaccines. The vaccine, called the Pfizer-BioNTech COVID-19 vaccine, has been authorized for emergency use in numerous countries around the world.
Fundamental View
The COVID-19 pandemic was a windfall opportunity for BioNTech and other mRNA vaccine manufacturers. In the heat of the pandemic, BNTX’s EPS grew from zero to nearly $16 per share.
The stock reacted accordingly, rising from $12 to over $400 a share in just months. However, unfortunately for BNTX investors, equities tend to be forward-looking devices rather than backward looking mechanisms. From that perspective, the picture is less rosy. This year, Zacks Consensus Analyst Estimates suggest that BNTX’s earnings will dive 70% year-over-year.
What’s worse is that recent revisions are moving in the wrong direction. Over the past 90 days, Zacks Consensus Analyst Estimates have dropped precipitously.
Technical View
Sometimes, its important to focus on how a stock reacts to earnings, rather than the earnings themselves. Over the past two quarters, BNTX has beat consensus analyst estimates. However, shares are lagging and trading near multi-year lows.
Relatively speaking, BNTX is -25% over the past twelve months while the S&P 500 is only -14%.
Bottom Line
BNTX is ranked a lowly 5 for a reason. Earnings have peaked, COVID hysteria has subsided, and the technical picture is lagging. All else being equal, expect BNTX shares to underperform over the next year.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s an American AI company that’s riding low right now, but it has rounded up clients like BMW, GE, Dell Computer, and Bosch. It has prospects for not just doubling but quadrupling in the year to come. Of course, all our picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Overview
Zacks Rank #5 (Strong Sell) stock BioNTech (BNTX) is a German biotech firm that develops and commercializes immunotherapies and innovative cancer treatments based on individualized therapies and precision medicine. The company was founded in 2008 and is based in Mainz, Germany.
BioNTech was relatively obscure until the company partnered with pharmaceutical juggernaut Pfizer (PFE) to develop one of the first mRNA COVID-19 vaccines. The vaccine, called the Pfizer-BioNTech COVID-19 vaccine, has been authorized for emergency use in numerous countries around the world.
Fundamental View
The COVID-19 pandemic was a windfall opportunity for BioNTech and other mRNA vaccine manufacturers. In the heat of the pandemic, BNTX’s EPS grew from zero to nearly $16 per share.
The stock reacted accordingly, rising from $12 to over $400 a share in just months. However, unfortunately for BNTX investors, equities tend to be forward-looking devices rather than backward looking mechanisms. From that perspective, the picture is less rosy. This year, Zacks Consensus Analyst Estimates suggest that BNTX’s earnings will dive 70% year-over-year.
What’s worse is that recent revisions are moving in the wrong direction. Over the past 90 days, Zacks Consensus Analyst Estimates have dropped precipitously.
Technical View
Sometimes, its important to focus on how a stock reacts to earnings, rather than the earnings themselves. Over the past two quarters, BNTX has beat consensus analyst estimates. However, shares are lagging and trading near multi-year lows.
Relatively speaking, BNTX is -25% over the past twelve months while the S&P 500 is only -14%.
Bottom Line
BNTX is ranked a lowly 5 for a reason. Earnings have peaked, COVID hysteria has subsided, and the technical picture is lagging. All else being equal, expect BNTX shares to underperform over the next year.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s an American AI company that’s riding low right now, but it has rounded up clients like BMW, GE, Dell Computer, and Bosch. It has prospects for not just doubling but quadrupling in the year to come. Of course, all our picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Get the latest research report on PFE - FREE
Get the latest research report on BNTX - FREE